RxDoctor Payments Data

Stephanie Fountain, MD

Critical Care Medicine · Fargo, NDNPI 1528405917

Payments from drug & device makers

What this record shows

This record is dominated by education: $9,000 of the $13,904 with a category attached, or 64.7%. Intuitive Surgical accounts for 74.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $10,418 and has fallen 89.5% since, to $1,095 in 2025.

$13,904in general payments, 2019–2025

Across 108 payments — averaging $128.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$10K
  • Olympus Corporation Of The Americas$1K
  • Vantive US Healthcare LLC$1K
  • GSK$375
  • AstraZeneca$336
  • Boehringer Ingelheim$280
  • plus $369 from 15 others

What the payments were for

  • Travel & lodging$3,14423%
  • Food & beverage$1,76013%
  • Education$9,00065%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few critical care medicine providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$40,074
Medicare patients
269
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$25,071
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$3,218
Albuterol Sulfate HfaAlbuterol Sulfate33$1,738
Ipratropium Bromide18$965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$375$25,07119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care medicine providers in North Dakotaon file to place this against a meaningful peer group, so we don't.

Other critical care medicine in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →